23 June 2020: Lab/In Vitro Research
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
Xiaoqiu Wu 123BEF* , Fangfei Li 123AG** , Yongshu Li 1BF , Yuanyuan Yu 13DF , Chao Liang 13C , Baoting Zhang 4DE , Chuanzong Zhao 56B , Aiping Lu 12378AG* , Ge Zhang 123AG*DOI: 10.12659/MSM.925583
Med Sci Monit 2020; 26:e925583
Figure 6 The effect of XQ-P3 on the PD-1/PD-L1 interaction. (A) XQ-P3 gradually lost its binding to MDA-MB-231 PD-L1 OE cells when more PD-1 protein existed. MDA-MB-231 PD-L1 OE cells were preincubated with the indicated concentration of PD-1 protein before being incubated with Cy5-labeled XQ-P3 (250 nM). Competition binding was analyzed by flow cytometry. (B) T cells secreted elevated IL-2 after XQ-P3 treatment (n=3). RS, a random sequence served as a negative control of XQ-P3 aptamer.